Principal Financial Group
PTCT icon

Principal Financial Group’s PTC Therapeutics PTCT Stock Holding History

Principal Financial Group’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$44.2M Buy
541,635
+26,634
+5% +$1.92M 0.02% 572
2026
Q1 		$35.1M Buy
515,001
+36,104
+8% +$2.56M 0.02% 606
2025
Q4 		$36.4M Buy
478,897
+411,220
+608% +$29.9M 0.02% 586
2025
Q3 		$4.15M Buy
67,677
+13,677
+25% +$712K ﹤0.01% 1654
2025
Q2 		$2.64M Buy
54,000
+48,160
+825% +$2.29M ﹤0.01% 1754
2025
Q1 		$298K Sell
5,840
-115
-2% -$5.74K ﹤0.01% 1993
2024
Q4 		$269K Sell
5,955
-721
-11% -$30.9K ﹤0.01% 2056
2024
Q3 		$248K Sell
6,676
-5,646
-46% -$189K ﹤0.01% 2066
2024
Q2 		$377K Sell
12,322
-5,442
-31% -$176K ﹤0.01% 2019
2024
Q1 		$517K Buy
17,764
+290
+2% +$8.12K ﹤0.01% 1977
2023
Q4 		$482K Sell
17,474
-150
-0.9% -$3.43K ﹤0.01% 1959
2023
Q3 		$395K Buy
17,624
+323
+2% +$12K ﹤0.01% 1999
2023
Q2 		$704K Sell
17,301
-556
-3% -$27.2K ﹤0.01% 1891
2023
Q1 		$865K Sell
17,857
-212
-1% -$9.69K ﹤0.01% 1876
2022
Q4 		$690K Buy
18,069
+397
+2% +$16.5K ﹤0.01% 1913
2022
Q3 		$887K Buy
17,672
+529
+3% +$25.9K ﹤0.01% 1861
2022
Q2 		$687K Sell
17,143
-3,675
-18% -$129K ﹤0.01% 1988
2022
Q1 		$777K Buy
20,818
+543
+3% +$20.9K ﹤0.01% 2029
2021
Q4 		$807K Sell
20,275
-8,660
-30% -$331K ﹤0.01% 2026
2021
Q3 		$1.08M Buy
28,935
+1,596
+6% +$65.6K ﹤0.01% 1989
2021
Q2 		$1.16M Sell
27,339
-890
-3% -$38.1K ﹤0.01% 2008
2021
Q1 		$1.34M Sell
28,229
-1,404
-5% -$83.4K ﹤0.01% 1933
2020
Q4 		$1.81M Buy
29,633
+7,226
+32% +$426K ﹤0.01% 1814
2020
Q3 		$1.05M Sell
22,407
-1,145
-5% -$56.4K ﹤0.01% 1862
2020
Q2 		$1.2M Buy
23,552
+6,800
+41% +$334K ﹤0.01% 1799
2020
Q1 		$747K Buy
16,752
+666
+4% +$33.5K ﹤0.01% 1790
2019
Q4 		$772K Sell
16,086
-1,524
-9% -$64.8K ﹤0.01% 1874
2019
Q3 		$596K Buy
17,610
+1,637
+10% +$71.3K ﹤0.01% 1914
2019
Q2 		$718K Sell
15,973
-27,725
-63% -$1.09M ﹤0.01% 1891
2019
Q1 		$1.65M Buy
43,698
+1,367
+3% +$45.9K ﹤0.01% 1764
2018
Q4 		$1.45M Buy
42,331
+2,331
+6% +$83.8K ﹤0.01% 1759
2018
Q3 		$1.88M Buy
40,000
+3,354
+9% +$139K ﹤0.01% 1765
2018
Q2 		$1.24M Buy
36,646
+8,475
+30% +$264K ﹤0.01% 1817
2018
Q1 		$762K Buy
28,171
+3,704
+15% +$93.9K ﹤0.01% 1873
2017
Q4 		$408K Buy
+24,467
New +$414K ﹤0.01% 2002
2015
Q3 		– Sell
-5,836
Closed -$281K – 2215
2015
Q2 		$281K Buy
5,836
+1,920
+49% +$112K ﹤0.01% 1970
2015
Q1 		$238K Sell
3,916
-51
-1% -$3.11K ﹤0.01% 1982
2014
Q4 		$205K Buy
+3,967
New +$175K ﹤0.01% 2033

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Principal Financial Group's PTCT Position: Q2 2026 in Review

Principal Financial Group increased its PTC Therapeutics (PTCT) stake by 5.2% in Q2 2026, buying an estimated $1.92M and bringing the position to 541,635 shares worth $44.2M. The position accounts for 0.02% of the portfolio, ranked #572.

Principal Financial Group first reported a position in PTCT in Q4 2014 and has held it in 38 quarters since. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Principal Financial Group held 541,635 shares of PTC Therapeutics worth $44.2M as of Q2 2026.
  • Principal Financial Group bought 26,634 PTC Therapeutics shares in Q2 2026, an estimated $1.92M.
  • PTC Therapeutics made up 0.02% of Principal Financial Group's portfolio in Q2 2026, its #572 holding.
  • Principal Financial Group first reported a position in PTC Therapeutics in Q4 2014 and has held it in 38 quarters since.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.